Perspective Therapeutics Begins Front-loaded 20 mCi NET Cohort and 6 mCi FAP-α Dosing
Perspective Therapeutics dosed the first patient with [212Pb]VMT-α-NET in cohort four using a front-loaded 20 mCi regimen (6 mCi, 5 mCi, 5 mCi and 4 mCi) in SSTR2-positive neuroendocrine tumors and treated the first patient with [212Pb]PSV359 at 6 mCi every eight weeks in cohort three of the FAP-α solid tumor study.
1. First Patient Dosed in VMT-α-NET Cohort Four
Perspective Therapeutics administered [212Pb]VMT-α-NET to the first patient in cohort four of its Phase 1/2a study targeting unresectable or metastatic SSTR2-positive neuroendocrine tumors. This cohort utilizes a front-loaded cumulative dose of 20 mCi across four administrations (6 mCi, 5 mCi, 5 mCi and 4 mCi) to assess whether intensified initial dosing improves response kinetics, rate and tolerability.
2. Cohort Three Initiated in PSV359 Solid Tumor Study
The company also dosed the first patient with [212Pb]PSV359 at a fixed 6 mCi every eight weeks in cohort three of its Phase 1/2a dose-finding trial for FAP-α-expressing solid tumors. Cohort three’s opening follows a safety committee review of cohort two data and will evaluate safety, tolerability and preliminary anti-tumor activity over up to four doses.
3. Study Design and Upcoming Milestones
Both trials are multi-center, open-label dose-escalation and expansion studies assessing safety, tolerability and preliminary efficacy of radiolabeled 212Pb ligands. Interim data from earlier cohorts and pending results from cohort two of VMT-α-NET plus eight patients in PSV359 cohort three are expected later in 2026, with additional presentations planned.